KIF5A (Kinesin heavy chain isoform 5A) variants and mutations
KIF5A (also known as Kinesin heavy chain isoform 5A) is a human protein-coding gene encoding a kinesin heavy chain isoform 5A protein. It drives anterograde transport of organelles and proteins along axonal microtubules and is especially important in long motor neurons. Pathogenic variants can cause hereditary spastic paraplegia, axonal Charcot-Marie-Tooth disease, or amyotrophic lateral sclerosis depending on the affected region and mechanism. This analysis covers 1,237 KIF5A variants and mutations. Of these, 71% have computational variant effect predictions. Disease context includes hereditary spastic paraplegia 10, Autosomal dominant spastic paraplegia type 10, and amyotrophic lateral sclerosis. Example KIF5A variants include M1I, A2E, and A2G.
Variant analysis overview
- Gene: KIF5A
- Protein: Kinesin heavy chain isoform 5A
- UniProt accession: Q12840
- Organism: Homo sapiens
- Variants analyzed: 1237
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 1,109 unspecified-consequence records; 59 synonymous variants; 58 missense variants; 1 in-frame insertions; 3 splice-region variants; 2 stop-gained variants; 3 frameshift variants; 3 substitution
- Prediction scores: 873 variants have prediction scores (71% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hereditary spastic paraplegia 10, Autosomal dominant spastic paraplegia type 10, amyotrophic lateral sclerosis, myoclonus, intractable, neonatal, hereditary spastic paraplegia, Spastic paraplegia, inherited neurodegenerative disorder, Intellectual disability, autosomal dominant Charcot-Marie-Tooth disease type 2 due to KIF5A mutation, demyelinating polyneuropathy, familial infantile myoclonic epilepsy, Charcot-Marie-Tooth disease type 2.
Protein structure and variant hotspots
- Protein features: 1 domains; 1 binding sites; 2 post-translational modification sites.
- Structural context: 434 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable KIF5A variants
Examples include M1I, A2E, A2G, A2K, A2T, A2V, E3Q, E3E. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), rs2540481290, ClinGen CA385495561, ClinVar RCV003055199, Uncertain significance, Spastic paraplegia
- A2E (p.Ala2Glu), ExAC rs780433858, TOPMed rs780433858, gnomAD rs780433858, REVEL 0.35, CADD 25.80, Uncertain significance
- A2G (p.Ala2Gly), ExAC rs780433858, TOPMed rs780433858, gnomAD rs780433858, Uncertain significance
- A2K (p.Ala2Lys), rs2140150082, ClinGen CA2573148846, ClinVar RCV001934378, Ensembl rs2140150082, Uncertain significance, Spastic paraplegia
- A2T (p.Ala2Thr), TOPMed rs1881528033
- A2V (p.Ala2Val), rs780433858, ClinGen CA6652488, ClinVar RCV002027924, ClinVar RCV002548995, REVEL 0.30, CADD 24.10, Uncertain significance, Spastic paraplegia; Inborn genetic diseases; not provided
- E3Q (p.Glu3Gln), TOPMed rs1244142117, gnomAD rs1244142117, REVEL 0.25, CADD 24.70
- E3E (p.Glu3Glu), gnomAD 12-57550280-G-A, CADD 13.10
- T4N (p.Thr4Asn), gnomAD 12-57550282-C-A, REVEL 0.11, CADD 20.30
- T4I (p.Thr4Ile), gnomAD 12-57550282-C-T, REVEL 0.12, CADD 21.90
- T4T (p.Thr4Thr), rs1389593168, gnomAD 12-57550283-C-T, CADD 13.60
- N5D (p.Asn5Asp), rs755532095, ClinGen CA6652489, ClinVar RCV002894199, ClinVar RCV004983160, REVEL 0.10, CADD 22.30, Uncertain significance, Inborn genetic diseases; not provided; Spastic paraplegia
- N5N (p.Asn5Asn), rs1454798717, gnomAD 12-57550286-C-T, CADD 13.60
- N5K (p.Asn5Lys), gnomAD 12-57550286-C-A, REVEL 0.13, CADD 20.70
- N6D (p.Asn6Asp), TOPMed rs1434215781, gnomAD rs1434215781, REVEL 0.14, CADD 21.70
- N6I (p.Asn6Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N6H (p.Asn6His), gnomAD 12-57550287-A-C, REVEL 0.21, CADD 22.50
- N6N (p.Asn6Asn), gnomAD 12-57550289-C-T, CADD 13.50
- E7K (p.Glu7Lys), NCI-TCGA Cosmic COSV5406, cosmic curated COSV54060, Variant assessed as somatic; moderate impact.
- C8F (p.Cys8Phe), rs940856567, ClinGen CA385495700, ClinVar RCV004550692, REVEL 0.59, CADD 32.00, Uncertain significance, KIF5A-related disorder
- C8R (p.Cys8Arg), rs1881529054, ClinGen CA385495695, ClinVar RCV002304119, AlphaMissense 0.33, MetaLR 0.21, Uncertain significance, Spastic paraplegia
- C8S (p.Cys8Ser), Ensembl rs1881529054
- C8Y (p.Cys8Tyr), TOPMed rs940856567, gnomAD rs940856567, REVEL 0.53, CADD 31.00
- S9N (p.Ser9Asn), rs1376496207, gnomAD rs1376496207, REVEL 0.16, CADD 19.50, Variant assessed as somatic; moderate impact.
- p.Ser9dup, gnomAD 12-57550293-T-TGT, CADD 22.70
- I10V (p.Ile10Val), rs2140150109, ClinGen CA385495731, ClinVar RCV001914358, Ensembl rs2140150109, AlphaMissense 0.19, MetaLR 0.36, Uncertain significance, Spastic paraplegia
- I10F (p.Ile10Phe), gnomAD 12-57550299-A-T, REVEL 0.79, CADD 29.60
- I10I (p.Ile10Ile), rs781490660, gnomAD 12-57550301-C-A, CADD 14.50
- K11N (p.Lys11Asn), NCI-TCGA Cosmic COSV9967, cosmic curated COSV99672, Variant assessed as somatic; moderate impact.
- K11R (p.Lys11Arg), ExAC rs748864821, TOPMed rs748864821, gnomAD rs748864821, REVEL 0.17, CADD 23.40, Uncertain significance
- K11T (p.Lys11Thr), rs748864821, ClinGen CA6652491, ClinVar RCV002013088, ClinVar RCV004774602, REVEL 0.61, CADD 28.60, Uncertain significance, not provided; not specified; Spastic paraplegia
- L13V (p.Leu13Val), rs2540481365, ClinGen CA385495790, ClinVar RCV002961910, Uncertain significance, Spastic paraplegia
- L13F (p.Leu13Phe), gnomAD 12-57550308-C-T, REVEL 0.13, CADD 22.20
- C14F (p.Cys14Phe), Ensembl rs2140150117
- C14Y (p.Cys14Tyr), rs2140150117, ClinGen CA385495809, ClinVar RCV003752300, AlphaMissense 0.99, MetaLR 0.65, Uncertain significance, Spastic paraplegia
- R15* (p.Arg15Ter), rs2140150119, ClinGen CA385495845, ClinVar RCV002040379, Ensembl rs2140150119, Pathogenic
- R17Q (p.Arg17Gln), NCI-TCGA Cosmic COSV5406, cosmic curated COSV54060, Variant assessed as somatic; moderate impact.
- R17W (p.Arg17Trp), rs2140150123, ClinGen CA385495879, ClinVar RCV001752452, ClinVar RCV005095013, AlphaMissense 1.00, MetaLR 0.83, Uncertain significance, Spastic paraplegia; not provided
- P18S (p.Pro18Ser), rs770302674, ClinGen CA6652492, NCI-TCGA Cosmic COSV5405, cosmic curated COSV54057, REVEL 0.85, CADD 26.90, Uncertain significance, Spastic paraplegia
- P18P (p.Pro18Pro), rs1432379331, gnomAD 12-57550325-C-T, CADD 12.50
- L19L (p.Leu19Leu), rs2140150135, gnomAD 12-57550328-G-A, CADD 8.99
- N20H (p.Asn20His), Ensembl rs2140150139
- N20S (p.Asn20Ser), Ensembl rs2140150143
- N20K (p.Asn20Lys), gnomAD 12-57550331-C-G, REVEL 0.57, CADD 24.90
- N20N (p.Asn20Asn), rs200876187, gnomAD 12-57550331-C-T, CADD 13.80
- Q21K (p.Gln21Lys), gnomAD 12-57550332-C-A, REVEL 0.15, CADD 20.40
- A22G (p.Ala22Gly), ExAC rs745558435, gnomAD rs745558435, Uncertain significance
- A22T (p.Ala22Thr), gnomAD rs1371053668, REVEL 0.12, CADD 22.40
- A22V (p.Ala22Val), rs745558435, ClinGen CA385495989, ClinVar RCV001755195, ExAC rs745558435, AlphaMissense 0.24, MetaLR 0.16, Uncertain significance, not provided
- A22S (p.Ala22Ser), gnomAD 12-57550335-G-T, REVEL 0.10, CADD 17.70
- A22A (p.Ala22Ala), rs2140150161, gnomAD 12-57550337-T-C, CADD 12.50
- E23K (p.Glu23Lys), Ensembl rs2140150164
- L25Q (p.Leu25Gln), ExAC rs771847226, gnomAD rs771847226, REVEL 0.16, CADD 21.20
- L25R (p.Leu25Arg), ExAC rs771847226, gnomAD rs771847226, REVEL 0.14, CADD 21.60, Uncertain significance, Spastic paraplegia
- L25V (p.Leu25Val), rs1389822103, ClinGen CA385496033, ClinVar RCV003752461, REVEL 0.08, CADD 19.40, Uncertain significance, Spastic paraplegia
- R26W (p.Arg26Trp), rs2540481412, ClinGen CA385496053, ClinVar RCV002469839, NCI-TCGA TCGA novel, Uncertain significance, not provided
- G27R (p.Gly27Arg), rs2540481413, ClinGen CA385496078, ClinVar RCV002303259, REVEL 0.48, CADD 29.10, Uncertain significance, Spastic paraplegia
- G27A (p.Gly27Ala), gnomAD 12-57550351-G-C, REVEL 0.49, CADD 24.90
- D28E (p.Asp28Glu), cosmic curated COSV54059, TOPMed rs1161092929, gnomAD rs1161092929, REVEL 0.27, CADD 23.10, Uncertain significance, Spastic paraplegia
- D28G (p.Asp28Gly), Ensembl rs2140150185
- D28N (p.Asp28Asn), Ensembl rs2140150181
- D28D (p.Asp28Asp), gnomAD 12-57550355-C-T, CADD 14.70
- K29E (p.Lys29Glu), Ensembl rs2140150192
- K29M (p.Lys29Met), rs2140150198, ClinGen CA385496134, ClinVar RCV001980485, Ensembl rs2140150198, AlphaMissense 0.27, MetaLR 0.34, Uncertain significance, Spastic paraplegia
- K29R (p.Lys29Arg), gnomAD 12-57550357-A-G, REVEL 0.24, CADD 23.30
- K29K (p.Lys29Lys), gnomAD 12-57550358-G-A, CADD 13.60
- F30L (p.Phe30Leu), 1000Genomes rs573410126, ExAC rs573410126, gnomAD rs573410126, REVEL 0.46, CADD 25.50
- I31M (p.Ile31Met), TOPMed rs923503057, gnomAD rs923503057, REVEL 0.20, CADD 22.20, Uncertain significance, Spastic paraplegia
- I31T (p.Ile31Thr), rs199955108, ClinGen CA6652497, ClinVar RCV003589161, ExAC rs199955108, REVEL 0.44, CADD 28.50, Uncertain significance, Spastic paraplegia
- I31I (p.Ile31Ile), rs923503057, gnomAD 12-57550364-C-T, CADD 14.30
- P32P (p.Pro32Pro), gnomAD 12-57550367-C-T, CADD 15.10
- I33F (p.Ile33Phe), rs540463538, 1000Genomes rs540463538, REVEL 0.27, AlphaMissense 0.10, Variant assessed as somatic; moderate impact.
- I33V (p.Ile33Val), rs540463538, ClinGen CA385496245, ClinVar RCV003751135, AlphaMissense 0.10, MetaLR 0.37, Uncertain significance, Spastic paraplegia
- Q35K (p.Gln35Lys), rs2140150213, ClinGen CA385496288, ClinVar RCV001942646, Ensembl rs2140150213, AlphaMissense 0.08, MetaLR 0.17, Uncertain significance, Spastic paraplegia
- G36R (p.Gly36Arg), NCI-TCGA Cosmic COSV5405, cosmic curated COSV54055, REVEL 0.19, CADD 23.90, Variant assessed as somatic; moderate impact.
- G36G (p.Gly36Gly), gnomAD 12-57550379-G-T, CADD 14.70
- D38G (p.Asp38Gly), Ensembl rs2140150216, REVEL 0.47, CADD 32.00
- D38N (p.Asp38Asn), gnomAD 12-57550383-G-A, REVEL 0.16, CADD 24.40
- D38H (p.Asp38His), gnomAD 12-57550383-G-C, REVEL 0.41, CADD 32.00
- S39I (p.Ser39Ile), NCI-TCGA Cosmic COSV5405, cosmic curated COSV54051, Variant assessed as somatic; moderate impact.
- S39S (p.Ser39Ser), rs1390200631, gnomAD 12-57550388-C-T, CADD 15.50
- V40I (p.Val40Ile), rs1565690660, ClinGen CA385496390, ClinVar RCV002023096, ClinVar RCV004721007, REVEL 0.24, CADD 23.20, Conflicting interpretations, Spastic paraplegia; not provided
- V40V (p.Val40Val), rs768642667, gnomAD 12-57550391-C-A, CADD 14.30
- V41I (p.Val41Ile), rs1881531764, ClinGen CA385496403, NCI-TCGA Cosmic COSV5405, cosmic curated COSV54054, REVEL 0.07, CADD 17.60, Uncertain significance, Spastic paraplegia
- I42M (p.Ile42Met), rs149569914, ClinGen CA6652500, ClinVar RCV001111424, ClinVar RCV001303301, REVEL 0.19, CADD 19.40, Uncertain significance, Spastic paraplegia; Hereditary spastic paraplegia 10; not provided
- I42V (p.Ile42Val), rs1207026111, ClinGen CA385496419, ClinVar RCV003881170, TOPMed rs1207026111, REVEL 0.08, CADD 20.40, Likely benign, Spastic paraplegia
- I42T (p.Ile42Thr), gnomAD 12-57550396-T-C, REVEL 0.36, CADD 29.80
- G43A (p.Gly43Ala), rs1800918984, ClinGen CA385496450, ClinVar RCV003868423, ClinVar RCV005256935, AlphaMissense 0.10, MetaLR 0.29, Uncertain significance, not provided; Spastic paraplegia
- G43W (p.Gly43Trp), gnomAD 12-57550398-G-T, REVEL 0.46, CADD 32.00
- G43R (p.Gly43Arg), gnomAD 12-57550398-G-A, REVEL 0.19, CADD 32.00
- G44R (p.Gly44Arg), gnomAD 12-57563439-G-A, REVEL 0.47, CADD 32.00
- G44E (p.Gly44Glu), gnomAD 12-57563440-G-A, REVEL 0.40, CADD 29.70
- G44G (p.Gly44Gly), gnomAD 12-57563441-G-A, CADD 9.22
- P46A (p.Pro46Ala), rs1881971668, ClinGen CA385492178, ClinVar RCV002606281, Ensembl rs1881971668, REVEL 0.19, CADD 19.90, Uncertain significance, Spastic paraplegia
- P46P (p.Pro46Pro), rs2140158738, gnomAD 12-57563447-A-G, CADD 4.75
- Y47* (p.Tyr47Ter), NCI-TCGA Cosmic COSV9967, Variant assessed as somatic; high impact.
- Y47C (p.Tyr47Cys), gnomAD 12-57563449-A-G, REVEL 0.84, CADD 28.30
- V48F (p.Val48Phe), gnomAD 12-57563451-G-T, REVEL 0.42, CADD 22.70
- V48D (p.Val48Asp), gnomAD 12-57563452-T-A, REVEL 0.51, CADD 24.20
- V48V (p.Val48Val), gnomAD 12-57563453-T-G, CADD 10.30
- F49F (p.Phe49Phe), gnomAD 12-57563456-T-C, CADD 11.50
- R51C (p.Arg51Cys), rs769763596, ClinGen CA6652518, ClinVar RCV001900170, ClinVar RCV002290782, REVEL 0.57, AlphaMissense 0.14, Uncertain significance, Inborn genetic diseases; Spastic paraplegia; Hereditary spastic paraplegia 10
- R51G (p.Arg51Gly), rs769763596, ClinGen CA385492338, ClinVar RCV002000482, ExAC rs769763596, AlphaMissense 0.14, MetaLR 0.64, Uncertain significance, Spastic paraplegia
- R51H (p.Arg51His), rs773336059, ClinGen CA6652519, ClinVar RCV001111425, ClinVar RCV002069798, REVEL 0.29, CADD 23.20, Conflicting interpretations, KIF5A-related disorder; Spastic paraplegia; Hereditary spastic paraplegia 10
- F53L (p.Phe53Leu), 1000Genomes rs536777412, ExAC rs536777412, TOPMed rs536777412, gnomAD rs536777412, REVEL 0.44, CADD 15.00, Uncertain significance, Spastic paraplegia
- F53S (p.Phe53Ser), rs1555177348, ClinGen CA385492401, ClinVar RCV000633016, Ensembl rs1555177348, AlphaMissense 0.99, MetaLR 0.77, Uncertain significance, Spastic paraplegia
- F53Y (p.Phe53Tyr), gnomAD 12-57563467-T-A, REVEL 0.61, CADD 27.40
- F53F (p.Phe53Phe), rs536777412, gnomAD 12-57563468-C-T, CADD 9.32
- P54L (p.Pro54Leu), Ensembl rs1881972414, REVEL 0.44, CADD 25.10
- P54R (p.Pro54Arg), Ensembl rs1881972414
- P55A (p.Pro55Ala), rs1169287923, ClinGen CA385492447, ClinVar RCV003751514, REVEL 0.33, CADD 23.60, Uncertain significance, Spastic paraplegia
- P55Q (p.Pro55Gln), TOPMed rs1014548294
- P55R (p.Pro55Arg), rs1014548294, ClinGen CA385492454, ClinVar RCV003866484, AlphaMissense 0.40, MetaLR 0.52, Uncertain significance, Spastic paraplegia
- P55S (p.Pro55Ser), gnomAD rs1169287923, REVEL 0.25, CADD 20.10
- N56H (p.Asn56His), rs1162282839, ClinGen CA385492467, ClinVar RCV001915912, ClinVar RCV005238055, REVEL 0.27, CADD 23.50, Uncertain significance, Spastic paraplegia; Inborn genetic diseases; not specified
- N56K (p.Asn56Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N56T (p.Asn56Thr), ExAC rs774510700, gnomAD rs774510700, REVEL 0.30, CADD 22.70
- N56D (p.Asn56Asp), gnomAD 12-57563475-A-G, REVEL 0.23, CADD 22.70
- N56I (p.Asn56Ile), gnomAD 12-57563476-A-T, REVEL 0.59, CADD 26.90
- N56N (p.Asn56Asn), gnomAD 12-57563477-C-T, CADD 10.10
- T57M (p.Thr57Met), rs759785671, ClinGen CA6652523, ClinVar RCV001997821, ExAC rs759785671, REVEL 0.52, CADD 25.30, Uncertain significance, Spastic paraplegia
- T57T (p.Thr57Thr), rs767814774, gnomAD 12-57563480-G-A, CADD 6.83
- T58I (p.Thr58Ile), NCI-TCGA Cosmic COSV5405, Variant assessed as somatic; moderate impact.
- T58S (p.Thr58Ser), gnomAD rs1348634786, REVEL 0.11, CADD 20.20
- T58T (p.Thr58Thr), gnomAD 12-57563483-T-A, CADD 9.69
- E60D (p.Glu60Asp), NCI-TCGA Cosmic COSV5405, REVEL 0.34, CADD 19.40, Variant assessed as somatic; moderate impact.
- E60Q (p.Glu60Gln), rs1881973323, ClinGen CA385492593, ClinVar RCV001093316, Ensembl rs1881973323, AlphaMissense 0.23, MetaLR 0.34, Uncertain significance, not provided
- E60E (p.Glu60Glu), rs200900180, gnomAD 12-57563489-G-A, CADD 9.65
- Q61* (p.Gln61Ter), gnomAD 12-57563490-C-T, CADD 38.00
- Q61Q (p.Gln61Gln), gnomAD 12-57563492-A-G, CADD 9.60
- Q61H (p.Gln61His), gnomAD 12-57563492-A-C, REVEL 0.33, CADD 21.20
- V62L (p.Val62Leu), rs2140158758, ClinGen CA385492644, ClinVar RCV001987532, Ensembl rs2140158758, REVEL 0.65, CADD 26.00, Uncertain significance, Spastic paraplegia
- Y63C (p.Tyr63Cys), UniProt VAR 058741, Pathogenic, in SPG10
- H64R (p.His64Arg), TOPMed rs975867260, REVEL 0.20, CADD 23.20
- H64H (p.His64His), gnomAD 12-57563501-T-C, CADD 9.88
- A65V (p.Ala65Val), ExAC rs756639633, gnomAD rs756639633, REVEL 0.24, CADD 21.80
- A65A (p.Ala65Ala), gnomAD 12-57563504-A-C, CADD 2.17
- A67P (p.Ala67Pro), rs2540492980, ClinGen CA385492793, ClinVar RCV003590582, Uncertain significance, Spastic paraplegia
- A67A (p.Ala67Ala), rs1357161558, gnomAD 12-57563510-C-A, CADD 10.60
- M68R (p.Met68Arg), rs1230201278, ClinGen CA385492850, ClinVar RCV002296935, AlphaMissense 0.13, MetaLR 0.19, Uncertain significance, Spastic paraplegia
- M68T (p.Met68Thr), rs1230201278, ClinGen CA385492848, ClinVar RCV002928394, gnomAD rs1230201278, REVEL 0.18, AlphaMissense 0.13, Uncertain significance, Spastic paraplegia
- Q69H (p.Gln69His), gnomAD rs1288040135
- I70T (p.Ile70Thr), gnomAD 12-57563518-T-C, REVEL 0.74, CADD 26.90
- K72R (p.Lys72Arg), rs2540492989, ClinGen CA385492974, ClinVar RCV003590500, Uncertain significance, Spastic paraplegia
- K72N (p.Lys72Asn), gnomAD 12-57563525-A-C, REVEL 0.26, CADD 27.20
- D73N (p.Asp73Asn), rs2540492992, ClinGen CA385492999, ClinVar RCV002289201, Likely pathogenic, Hereditary spastic paraplegia 10
- D73D (p.Asp73Asp), gnomAD 12-57563621-T-C, CADD 16.20
- D73E (p.Asp73Glu), gnomAD 12-57563621-T-A, REVEL 0.63, CADD 26.60
- V74A (p.Val74Ala), gnomAD 12-57563623-T-C, REVEL 0.70, CADD 27.70
- V74V (p.Val74Val), rs771052356, gnomAD 12-57563624-C-T, CADD 8.63
- L75V (p.Leu75Val), TOPMed rs1881977787
- L75F (p.Leu75Phe), gnomAD 12-57563625-C-T, REVEL 0.66, CADD 25.80
- A76T (p.Ala76Thr), TOPMed rs1881977913, REVEL 0.13, CADD 22.90
- A76G (p.Ala76Gly), gnomAD 12-57563629-C-G, REVEL 0.11, CADD 17.30
- A76A (p.Ala76Ala), rs774386161, gnomAD 12-57563630-T-C, CADD 13.40
- G77D (p.Gly77Asp), rs1060502525, ClinGen CA16613830, ClinVar RCV000460120, Ensembl rs1060502525, AlphaMissense 1.00, MetaLR 0.87, Uncertain significance, Spastic paraplegia
- Y78C (p.Tyr78Cys), rs2140158848, ClinGen CA385493245, ClinVar RCV002262388, Ensembl rs2140158848, REVEL 0.75, CADD 29.00, Uncertain significance, not provided
- Y78* (p.Tyr78Ter), gnomAD 12-57563636-C-A, CADD 37.00
- Y78Y (p.Tyr78Tyr), gnomAD 12-57563636-C-T, CADD 12.00
- N79S (p.Asn79Ser), rs1299838179, ClinGen CA385493278, ClinVar RCV001566522, ClinVar RCV001866002, REVEL 0.84, CADD 26.60, Uncertain significance, Spastic paraplegia; not provided
- G80G (p.Gly80Gly), gnomAD 12-57563642-C-T, CADD 13.20
- I82V (p.Ile82Val), rs2540493184, ClinGen CA385493353, ClinVar RCV003752511, CADD 3.82, Uncertain significance, Spastic paraplegia
- A84A (p.Ala84Ala), rs1340159221, gnomAD 12-57563654-T-C, CADD 9.99
- Y85C (p.Tyr85Cys), Ensembl rs1594912354
- G86G (p.Gly86Gly), rs759747024, gnomAD 12-57563660-A-G, CADD 11.80
- Q87E (p.Gln87Glu), rs2540493198, ClinGen CA385493459, ClinVar RCV002290229, Uncertain significance, Hereditary spastic paraplegia 10
- Q87K (p.Gln87Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q87R (p.Gln87Arg), rs2540493201, ClinGen CA385493467, ClinVar RCV002843953, Uncertain significance, Spastic paraplegia
- Q87Q (p.Gln87Gln), rs369673537, gnomAD 12-57563663-G-A, CADD 10.80
- T88A (p.Thr88Ala), rs2540493207, ClinGen CA385493489, ClinVar RCV002286509, Likely pathogenic, Peripheral neuropathy
- T88I (p.Thr88Ile), rs2540493214, ClinGen CA385493504, ClinVar RCV003318822, Pathogenic, not provided
- T88S (p.Thr88Ser), gnomAD 12-57563664-A-T, REVEL 0.86, CADD 25.90
- T88T (p.Thr88Thr), gnomAD 12-57563666-A-T, CADD 9.74
- S89Y (p.Ser89Tyr), rs2140158856, ClinGen CA385493524, ClinVar RCV001965509, Ensembl rs2140158856, AlphaMissense 0.98, MetaLR 0.65, Uncertain significance, Spastic paraplegia
- S89S (p.Ser89Ser), gnomAD 12-57563669-C-T, CADD 11.00
- S90L (p.Ser90Leu), rs1060502524, ClinGen CA16613834, ClinVar RCV000472975, ClinVar RCV003227755, AlphaMissense 1.00, MetaLR 0.82, Uncertain significance, not provided; Spastic paraplegia
- G91E (p.Gly91Glu), rs2540493234, ClinGen CA385493592, ClinVar RCV003026012, Uncertain significance, Spastic paraplegia
- G91G (p.Gly91Gly), gnomAD 12-57563675-G-A, CADD 9.79
- K92T (p.Lys92Thr), rs2140158867, ClinGen CA385493611, ClinVar RCV002013906, Ensembl rs2140158867, AlphaMissense 1.00, MetaLR 0.91, Uncertain significance, Spastic paraplegia
- K92K (p.Lys92Lys), rs1444478063, gnomAD 12-57563678-A-G, CADD 12.00
Public KIF5A analysis runs
- KIF5A analysis run — KIF5A (1,237 variants) — completed 2026-08-22